{
  "id": "5c73acea7c78d69471000085",
  "type": "yesno",
  "question": "Should dacomitinib be used for treatment of glioblastoma patients?",
  "ideal_answer": "No, dacomitinib has a limited single-agent activity in recurrent glioblastoma with EGFR amplification.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28575464",
    "http://www.ncbi.nlm.nih.gov/pubmed/30247945"
  ],
  "snippets": [
    {
      "text": "Expert opinion: Despite the poor global results of Dacomitinib in recurrent GB shown in a phase II trial, some patients had a significant benefit. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30247945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions: Dacomitinib has a limited single-agent activity in recurrent GB with EGFR amplification.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575464",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Despite the poor global results of Dacomitinib in recurrent GB shown in a phase II trial, some patients had a significant benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30247945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Despite the poor global results of Dacomitinib in recurrent GB shown in a phase II trial, some patients had a significant benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30247945",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}